22
NOV
2023
Northwest Biotherapeutics Provides Update On Final Preparations for Marketing Authorization Application
Comments : Off
BETHESDA, MD, November 22, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval... Read More